Heilongjiang ZBD Pharmaceutical Co., Ltd.
603567.SS
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.08B
Close$
$-1.70
132.5% downside
Current Fair Value
132.5% downsideOvervalued by 132.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.08 Billion |
|---|---|
| Enterprise Value | $8.26 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.45 |
| Beta | 0.28 |
| Outstanding Shares | 940,027,288 |
Return
| Return on Equity | -25.94% |
|---|---|
| Return on Assets | -15.18% |
| Return on Invested Capital | -25.79% |
Valuation & Multiples
| P/E Ratio | -3.26 |
|---|---|
| PEG | 8 |
| Price to Sales | - |
| Price to Book Ratio | 0.87 |
| Enterprise Value to Revenue | 21.76 |
| Enterprise Value to EBIT | -4.85 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.39 |
| Debt to Equity | 0.54 |
Revenue Sources
No data
Insider Trades
Next Earnings Call
Expected Date
October 31, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Heilongjiang ZBD Pharmaceutical Co., Ltd.
1,961 employees
CEO: Jiujiang Yan Heilongjiang ZBD Pharmaceutical Co., Ltd. is a Chinese pharmaceutical firm dedicated to the entire lifecycle of Traditional Chinese Medicine (TCM), from research and development to manufacturing and sales, exclusively within China. Its e...